PATE-G inhibitors are a class of chemical compounds that function by targeting and inhibiting the activity of the PATE-G protein. This protein is part of the PATE (Prostate And Testis Expressed) family, which is known for its role in various cellular processes, including cellular signaling and protein interactions. The inhibition of PATE-G involves intricate mechanisms at the molecular level, where inhibitors typically bind to specific active sites on the PATE-G protein, thereby altering its conformation and function. These inhibitors are designed to interact with the protein's specific structural features, including binding pockets and catalytic domains, which are crucial for its biological activity.
The development and study of PATE-G inhibitors involve advanced techniques in molecular biology and chemistry, such as structure-based drug design, molecular docking studies, and high-throughput screening. Researchers employ these techniques to identify potential inhibitory compounds and optimize their efficacy and selectivity. Additionally, the synthesis of PATE-G inhibitors often requires sophisticated organic chemistry methods to achieve the desired molecular structures and functionalities. This chemical class is characterized by a diverse range of molecular scaffolds and functional groups, which are tailored to achieve high binding affinity and specificity for the PATE-G protein. The ongoing research into PATE-G inhibitors continues to reveal new insights into their molecular interactions and potential applications in scientific research.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor, may modify MAPK/ERK pathway, potentially intersecting with PATE-G's role in cell signaling and proliferation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor, could affect cell growth and survival pathways, potentially linked to PATE-G's function. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor; might affect cell cycle regulation, potentially intersecting with PATE-G's role in cell proliferation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor; could affect protein degradation pathways, potentially linked to PATE-G's function. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
RAF kinase inhibitor; might influence cell signaling pathways where PATE-G is implicated, particularly in cell growth. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
BCR-ABL tyrosine kinase inhibitor; may influence cell proliferation pathways, possibly intersecting with PATE-G. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
EGFR inhibitor, could impact pathways intersecting with PATE-G's function in cell growth and proliferation. | ||||||